UNCY - Unicycive Therapeutics Inc
IEX Last Trade
0.3317
-0.011 -3.346%
Share volume: 1,183,547
Last Updated: Fri 30 Aug 2024 09:59:25 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.34
-0.01
-3.24%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-15 | 2022-11-14 | 2023-03-31 | 2023-05-16 | 2023-08-14 | 2023-11-14 | 2024-03-28 | |
| Total revenue | 0.000 | 0.000 | 951.000 K | 0.000 | 675.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 951.000 K | 0.000 | 675.000 K | 0.000 | 0.000 | 0.000 | |
| nan% | inf% | -100.00% | inf% | -100.00% | nan% | nan% | |||
| Operating expenses | 3.537 M | 3.636 M | 6.505 M | 5.325 M | 4.877 M | 4.322 M | 5.938 M | 6.312 M | |
| Selling general and admin | 1.604 M | 1.776 M | 1.702 M | 1.485 M | 1.847 M | 2.055 M | 2.566 M | 2.079 M | |
| Research and development | 1.933 M | 1.860 M | 4.803 M | 3.840 M | 3.030 M | 2.267 M | 3.372 M | 4.233 M | |
| Total expenses | 3.537 M | 3.636 M | 6.505 M | 5.325 M | 4.877 M | 4.322 M | 5.938 M | 6.312 M | |
| 2.80% | 78.91% | -18.14% | -8.41% | -11.38% | 37.39% | 6.30% | |||
| Operating income | -3.537 M | -3.636 M | -5.554 M | -5.325 M | -4.202 M | -4.322 M | -5.938 M | -6.312 M | |
| Ebit | -3.537 M | -3.636 M | -5.554 M | -5.325 M | -4.202 M | -4.322 M | -5.938 M | -6.312 M | |
| Pretax income | -3.537 M | -3.636 M | -5.557 M | -5.328 M | -14.575 M | -3.838 M | -4.333 M | -7.798 M | |
| 2.80% | 52.83% | -4.12% | 173.55% | -73.67% | 12.90% | 79.97% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -3.537 M | -3.636 M | -5.557 M | -5.328 M | -14.767 M | -4.441 M | -4.405 M | -6.931 M | |
| -2.80% | -52.83% | 4.12% | -177.16% | 69.93% | 0.81% | -57.34% | |||
| Net income | -3.537 M | -3.636 M | -5.557 M | -5.328 M | -14.767 M | -4.441 M | -4.405 M | -6.931 M | |
| -2.80% | -52.83% | 4.12% | -177.16% | 69.93% | 0.81% | -57.34% |